Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Pomalidomide: Genotype-Aware Myeloma Assays
2026-08-26
Pomalidomide and CC-4047 can support more informative multiple myeloma research when compound biology is paired with genetically diverse cell models. This guide translates mutational landscape data into practical assay design, model selection, and evidence-aware interpretation.
-
KG-501 as a Causal Probe of CREB–KIX Signaling
2026-08-26
KG-501 is a small-molecule CREB–CBP interaction inhibitor that can distinguish transcriptional coactivator dependence from upstream receptor signaling. This article develops an assay-centered framework linking KG-501 to macrophage polarization and colitis-associated colorectal cancer research while defining key interpretive limitations.
-
JNJ-10198409: PDGF Kinase Logic for Translation
2026-08-25
A mechanistic and translational framework for using JNJ-10198409 to interrogate PDGF-BB receptor signaling, connect kinase engagement with cellular phenotypes, and design more interpretable oncology, vascular, and fibrosis studies. The discussion also draws a carefully bounded conceptual lesson from recent Rice stripe virus research: pathway context, phosphorylation dynamics, and biological timing can determine how kinase perturbation is interpreted.
-
SmD2 Acetylation Links Splicing to PARP Sensitivity
2026-08-25
This study identifies SmD2 acetylation as a regulatory connection between core spliceosome activity, BRCA1/FANC cassette exons, and PARP inhibitor response in hepatocellular carcinoma. Its preclinical data support combining HDAC-directed intervention with PARP inhibition, while also highlighting the need for biomarker and safety validation.
-
Chlorin e6 (Ce6) in Photodynamic Therapy
2026-08-24
Chlorin e6 is a Ce6 photosensitizer used in anticancer photodynamic therapy research. Light-activated Ce6 generates reactive oxygen species that can promote cytotoxicity, cellular apoptosis induction, and, in liposomal breast cancer models, pyroptosis and antitumor immune effects.
-
Prestained Protein Marker: Triple-Color Workflow
2026-08-24
The Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) provides visible molecular weight references for SDS-PAGE separation and Western blot transfer checks. It is intended for protein sizing and transfer monitoring, not absolute protein quantitation or workflows that specifically require an EDTA-containing marker.
-
DOPE Links Membrane Fusion to Fungal Ferroptosis
2026-08-23
1,2-Dioleoyl-sn-glycero-3-PE (DOPE) is more than a helper lipid for nucleic acid delivery. Evidence from Magnaporthe oryzae shows that phosphatidylethanolamine supplementation can partially restore developmental ferroptotic cell death and pathogenicity defects, creating a useful bridge between membrane biophysics, lipid metabolism, and translational formulation strategy.
-
PEO Chain Density and Uremic Toxin Adsorption
2026-08-22
The reference study maps how end-tethered methoxy-terminated poly(ethylene oxide) films interact with a chemically diverse panel of uremic toxins, including 4-ethylphenyl sulfate. Its key contribution is showing that adsorption depends more on toxin structure than on solution abundance alone, informing the design of low-fouling biomaterials for renal failure and blood-contacting devices.
-
Toremifene Citrate: ER Assay Workflows
2026-08-22
Build more reproducible estrogen receptor experiments with Toremifene Citrate, from ERα/ERβ binding assays to breast cancer cell proliferation studies. This guide connects concentration selection, formulation, controls, and translational interpretation while highlighting where toremifene complements or differs from tamoxifen.
-
RapaLink-1: Durable mTOR Control Across Models
2026-08-21
RapaLink-1 offers a mechanistically differentiated approach to mTOR inhibition by combining FKBP12 engagement with kinase-pocket binding. This article examines how its bivalent design can inform cancer research, glioma studies, and carefully controlled investigations of mTOR-dependent embryonic dormancy.
-
CP-673451: Selective PDGFRα/β Inhibitor Workflow
2026-08-20
CP-673451 combines nanomolar PDGFR potency with a focused kinase profile, making it useful for linking receptor phosphorylation to angiogenesis and tumor phenotypes. This workflow shows how to apply it in ATRX-stratified glioma studies, ligand-specific vascular assays, and xenograft research while avoiding common interpretation and handling errors.
-
Measuring Drug Responses in Cancer In Vitro
2026-08-20
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable readouts in cancer drug studies. Its central contribution is a response framework that separates growth inhibition from cell killing, improving interpretation of timing, mechanism, and apparent drug sensitivity.
-
Diphenyleneiodonium Chloride: Applied Assay Workflows
2026-08-19
Diphenyleneiodonium chloride is a dual-purpose research tool for separating oxidase-linked redox effects from GPR3-driven cAMP signaling. This practical guide covers stock preparation, cell and plant assay design, reference-study translation, and troubleshooting for more interpretable oxidative stress experiments.
-
Tunicamycin, ER Stress, and the FKBP9 Resistance Axis
2026-08-19
Tunicamycin is more than a laboratory ER-stress reagent: it is a mechanistic probe for connecting N-glycosylation failure, unfolded protein response signaling, and stress resistance in translational cancer research. This article integrates the FKBP9 glioblastoma study with practical assay strategy, macrophage biology, and product-selection guidance.
-
Masitinib (AB1010): Practical KIT/PDGFR Guide
2026-08-18
Masitinib (AB1010), SKU A2942, provides a DMSO-compatible research tool for examining KIT, PDGFRα, and PDGFRβ inhibition in biochemical, cellular, mast-cell, and cancer biology workflows. It is not appropriate for aqueous or ethanol-based protocols, broad-spectrum kinase screens, clinical dosing decisions, or assays requiring paper-specific validation that is not available here.